FDA clears first antisense oligonucleotide for chronic hepatitis B
The FDA has approved Hibsago (bepirovirsen) injection, given with existing antiviral therapy, for certain adults with chronic hepatitis B who do not have cirrhosis. The decision gives clinicians a new treatment option built around a different biologic target: instead of simply suppressing viral replication, the drug is designed to reduce the viral templates and proteins that keep infection active in the body.
For patients who have spent years taking hepatitis B medication to keep the virus quiet, the approval changes the treatment conversation. The label is limited to adults who have already been on HBV antiviral therapy for at least six months, have suppressed HBV levels in blood, and have hepatitis B surface antigen levels of 3,000 IU/mL or less as measured by an FDA-authorized test.
A treatment aimed at the virus’s genetic instructions
Chronic hepatitis B is a long-term liver infection caused by HBV. Left unchecked, it can progress to cirrhosis and raise the risk of liver cancer. Current antiviral therapy can suppress viral replication, but many patients remain tied to long-term treatment because the infection persists in a form that is difficult to eliminate completely.
Hibsago is the first FDA-approved antisense oligonucleotide for chronic hepatitis B. In practical terms, that means it is designed to interfere with the genetic instructions the virus uses to make copies of itself and produce viral proteins. By lowering both the amount of virus and the amount of hepatitis B surface antigen in the body, the drug aims to move selected patients closer to a state in which treatment can potentially be stopped under careful monitoring.
The biologic logic is straightforward. HBV persistence depends not only on ongoing replication, but also on continued production of viral proteins that help maintain infection. Lowering those signals may reduce the antigen burden enough for some patients to maintain control after treatment ends.
Trial results point to a narrow but meaningful stopping pathway
Researchers studied Hibsago in two clinical trials comparing it with placebo. The drug is injected under the skin for up to 24 weeks and is taken alongside a patient’s existing hepatitis B medicine. After the final Hibsago injection, patients continue the background antiviral therapy for at least 24 more weeks. Some patients may then stop their existing medicine if they meet certain health and laboratory requirements.
Across the two trials, 24% of patients who received Hibsago met the requirements to stop their existing medicine, while none in the placebo group did. Twenty-four weeks after all hepatitis B treatment had been stopped, 19% of patients who had received Hibsago still had the virus under control, and hepatitis B surface antigen was not detectable in blood.
Those numbers matter because they show a biologic effect beyond simple suppression. The endpoint is not cure in the broad sense, and it is not durability for every treated patient. It is a defined subset of patients reaching a low-antigen, controlled state after therapy ends, which is the kind of result hepatology has been working toward for years.
Patient selection and monitoring are central to safe use
The approval comes with a companion diagnostic, the Roche Elecsys HBsAg II quant II RxDx assay, to aid in selecting patients for treatment with antiviral therapy in line with the drug label and to help monitor them during treatment. Selection is not a minor detail here. It is central to the way the drug is meant to be used, because the approved population is narrow and depends on both virologic suppression and a specific surface antigen threshold.
Safety monitoring is equally important. Hibsago carries a boxed warning for serious liver reactions and low platelet counts, the latter of which can raise the risk of potentially life-threatening bleeding. Additional warnings cover worsening kidney function, serious inflammatory adverse reactions such as vasculitis, and serious risks if the injection is not administered properly.
Patients need regular blood tests and ongoing follow-up before and during treatment. In a drug designed to alter the course of a chronic viral infection, the monitoring burden is not peripheral; it is part of the treatment itself.
Adverse events and bedside implications
The most common side effects, excluding laboratory abnormalities, were injection site reactions, fever, fatigue, and headache. Those reactions are familiar enough in antiviral and immunomodulatory treatment programs, but the boxed warning signals a more serious layer of risk that will demand careful clinician attention.
The concern is not simply whether the drug lowers antigen. It is whether that benefit can be achieved without provoking liver injury, thrombocytopenia, kidney dysfunction, or inflammatory complications serious enough to offset the gain. In real-world practice, the drug’s place will depend on whether clinicians can identify the right patients, follow them closely, and stop treatment only when the laboratory and clinical picture supports it.
For adults with chronic hepatitis B who fit the label, the approval opens a path that goes beyond indefinite viral suppression. It does not remove the need for antiviral therapy in most patients, and it does not erase the seriousness of chronic HBV. It does offer a new mechanism, a new diagnostic gate, and a small but real chance for some patients to discontinue background therapy while still keeping the virus under control.
The FDA granted Hibsago Fast Track, Breakthrough Therapy, and Priority Review designations, and granted approval to GSK plc. The designation history reflects the unmet need in chronic hepatitis B, where durable off-treatment control has remained difficult to achieve and where long-term management still leaves many patients facing years of ongoing medication and surveillance.